Effects of captopril and valsartan on ventricular remodeling and inflammatory cytokines after interventional therapy for AMI

The effects of captopril and valsartan on ventricular remodeling and inflammatory cytokines after interventional therapy for acute myocardial infarction (AMI) were investigated. A total of 94 patients with AMI admitted to Honggang Hospital of Dongying from July 2016 to June 2017 were selected as study subjects. The patients were treated with interventional therapy and randomly divided into the observation group (n=47) and the control group (n=47). The control group received aspirin after operation, while the observation group received captopril and valsartan after operation. Three-dimensional ultrasonography was performed to evaluate ventricular remodeling. The related parameters included left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), left ventricular ejection fraction (LVEF), end-systolic sphericity index/end-diastolic sphericity index (ESSI/EDSI), systolic dyssynchrony index (SDI), diastolic dyssynchrony index (DDI), dispersion end systole (DISPES), DDI-late and DISPED-late. The levels of inflammatory cytokines were determined by enzyme-linked immunosorbent assay (ELISA). The incidence of adverse reactions after treatment was compared. After treatment, LVEF in the control group was significantly lower than that in the observation group, while LVEDV, LVESV and the ratio of early diastolic (E) and late diastolic (A) (E/A) in the control group were significantly higher than those in the observation group (p<0.05). EDSI, DDI-late and DISPED-late in the control group were significantly higher than those in the observation group (p<0.05). ESSI, SDI and DISPES in the control group were significantly higher than those in the observation group (p<0.05). The levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) in the observation group were significantly lower than those in the control group at 1, 4 and 8 weeks after treatment (p<0.05). The administration of captopril and valsartan after interventional therapy for AMI can effectively improve the cardiac function of patients, improve the synchronism of left ventricular diastole and contraction, and reduce the level of inflammation. It is safe and reliable, and has important clinical significance.